Current Legislation Search

SB465-FN

Bill Details

Title: classifying xylazine as a schedule III controlled drug.

Sponsors: (Prime) Gannon (R), Abbas (R), Birdsell (R), Carson (R), Rochefort (R), McConkey (R), Lilli Walsh (R), Vose (R), Roy (R), Rhodes (R)

LSR Number: 26-2002

General Status: HOUSE

House:

Committee: Environment and Agriculture

Due Out: 4/16/2026

Status: INEXPEDIENT TO LEGISLATE

Senate:

Committee: Judiciary

Floor Date: 3/5/2026

Status: PASSED/ADOPTED WITH AMENDMENT

Documents

Subscribe To SB465-FN

Docket

Bill Versions

Introduced [PDF]

As Amended by the Senate [PDF]

Amendments

2026-0842s [PDF]

Hearing Reports

Roll Calls

No House Roll Calls

No Senate Roll Calls:

Bill Docket

Body

Description

Introduced 01/07/2026 and Referred to Judiciary; SJ 1

Hearing: 02/10/2026, Room 100, SH, 01:30 pm; SC 5A

Committee Report: Ought to Pass with Amendment #2026-0842s, 03/05/2026; Vote 5-0; CC; SC 8

Committee Amendment #2026-0842s, AA, VV; 03/05/2026; SJ 5

Ought to Pass with Amendment #2026-0842s, MA, VV; OT3rdg; 03/05/2026; SJ 5

Introduced (in recess of) 03/12/2026 and referred to Environment and Agriculture HJ 8

Public Hearing: 03/31/2026 01:30 pm GP 153

Full Committee Work Session: 04/07/2026 01:00 pm GP 153

Executive Session: 04/14/2026 01:00 pm GP 153

Majority Committee Report: Inexpedient to Legislate 04/14/2026 (Vote 11-5; RC)

Minority Committee Report: Ought to Pass

Inexpedient to Legislate: MA VV 04/23/2026 HJ 11